Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016016774) CRYSTALLINE FORMS OF CANAGLIFLOZIN
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/016774 International Application No.: PCT/IB2015/055559
Publication Date: 04.02.2016 International Filing Date: 22.07.2015
IPC:
C07D 409/10 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
Applicants:
SUN PHARMACEUTICAL INDUSTRIES LIMITED [IN/IN]; Sun House, Plot No. 201 B/1 Western Express Highway Goregaon (E) Mumbai, Maharashtra 400 063, IN
Inventors:
SANTRA, Ramkinkar; IN
NAGDA, Devendra, Prakash; IN
THAIMATTAM, Ram; IN
ARYAN, Satish, Kumar; IN
SINGH, Tarun, Kumar; IN
PRASAD, Mohan; IN
GANGULY, Somenath; IN
WADHWA, Deepika; IN
Priority Data:
2156/DEL/201431.07.2014IN
Title (EN) CRYSTALLINE FORMS OF CANAGLIFLOZIN
(FR) FORMES CRISTALLINES DE CANAGLIFLOZINE
Abstract:
(EN) The present invention relates to crystalline forms of canagliflozin, processes for their preparation, and their use for the treatment of type 2 diabetes mellitus. A crystalline Form R3 pf canagliflozin hyrate. The crystalline Form R-3 canagliflozin hydrate, characterized by an X-ray powder diffraction peaks having d-spacing values at about 9.2,4.1,4.5, and 7.2 Å.
(FR) La présente invention concerne des formes cristallines de canagliflozine, des procédés pour leur préparation, et leur utilisation pour le traitement du diabète sucré de type 2. Une forme cristalline R1 d'hémihydrate de canagliflozine. La forme cristalline R1 d'hémihydrate de canagliflozine de la revendication 1, caractérisée par des pics de diffraction des rayons X sur poudre ayant des valeurs d'espacement d à environ 3,1, 3,7, 4,6, et 8,9 A.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)